Neurology News

Canadian-based Neurolytixs Inc. announced it has secured a United States patent for technology that can identify mild traumatic brain injuries more accurately and rapidly, particularly in young athletes with concussions.

Vamorolone demonstrated efficacy and safety in the treatment of boys with Duchenne muscular dystrophy over a 24-week treatment period and may be safer than prednisone, according to a study published in JAMA Neurology.

Digital therapeutics company Theranica announced it has received $45 million in investor funding, which the company will use to finance commercial expansion of its prescription migraine treatment device, Nerivio.

In the U.S., the use of carotid artery stenting has never been as widespread as that of carotid endarterectomy, which is partly a function of the CMS coverage decision. That may be about to change.

A deep-learning model has the potential to predict an individual’s response to antiseizure medications and may inform treatment selection in patients with newly diagnosed epilepsy, researchers reported in JAMA Neurology.

Introducing electroconvulsive therapy earlier in a treatment course for major depressive disorder or bipolar disorder may lead to improvements in clinical outcomes, according to a study published in the Journal of Clinical Psychiatry.

Aptinyx Inc. announced it has completed enrollment in the company’s ongoing phase 2 study of NYX-458, an oral treatment for cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

In the AXIOMATIC-SSP trial, milvexian, a novel factor XIa inhibitor, was protective against ischemic stroke with no increased risk for intracranial hemorrhage compared with placebo in patients requiring secondary prevention.

Mortality rates were significantly higher among veterans with drug-resistant epilepsy compared with other veterans and the general United States population, researchers reported in JAMA Neurology.

Alpha Cognition Inc. has announced positive results from a bioequivalence study with Alpha-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s disease.